These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37523661)

  • 1. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
    Colombo N; Lorusso D; Monk BJ; Slomovitz B; Hasegawa K; Nogueira-Rodrigues A; Zale M; Okpara CE; Barresi G; McKenzie J; Makker V
    Oncologist; 2024 Jan; 29(1):25-35. PubMed ID: 37523661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.
    Makker V; Taylor MH; Oaknin A; Casado Herraez A; Orlowski R; Dutta L; Ren M; Zale M; O'Malley DM
    Oncologist; 2021 Sep; 26(9):e1599-e1608. PubMed ID: 34190370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.
    Motzer R; George S; Merchan JR; Hutson TE; Song X; Perini RF; Xie R; Bapat U; Puente J
    Oncologist; 2023 Jun; 28(6):501-509. PubMed ID: 36866412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
    Makker V; Colombo N; Casado Herráez A; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay S; Ray-Coquard I; Shapira-Frommer R; Ushijima K; Sakata J; Yonemori K; Kim YM; Guerra EM; Sanli UA; McCormack MM; Smith AD; Keefe S; Bird S; Dutta L; Orlowski RJ; Lorusso D;
    N Engl J Med; 2022 Feb; 386(5):437-448. PubMed ID: 35045221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
    Yonemori K; Fujiwara K; Hasegawa K; Yunokawa M; Ushijima K; Suzuki S; Shikama A; Minobe S; Usami T; Kim JW; Kim BG; Wang PH; Chang TC; Yamamoto K; Han S; McKenzie J; Orlowski RJ; Miura T; Makker V; Man Kim Y
    J Gynecol Oncol; 2024 Mar; 35(2):e40. PubMed ID: 38302725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.
    Yonemori K; Yunokawa M; Ushijima K; Sakata J; Shikama A; Minobe S; Usami T; Enomoto T; Takehara K; Hasegawa K; Yamagami W; Yamamoto K; Han S; Dutta L; Orlowski R; Miura T; Makker V; Fujiwara K
    Cancer Sci; 2022 Oct; 113(10):3489-3497. PubMed ID: 35612971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
    J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis.
    Tochigi M; Shigeta S; Shimada M; Miyahara S; Hasegawa-Minato J; Shibuya Y; Ishibashi M; Hashimoto C; Tokunaga H; Yaegashi N
    Tohoku J Exp Med; 2024 Feb; 262(2):85-95. PubMed ID: 38008437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
    Makker V; Taylor MH; Aghajanian C; Oaknin A; Mier J; Cohn AL; Romeo M; Bratos R; Brose MS; DiSimone C; Messing M; Stepan DE; Dutcus CE; Wu J; Schmidt EV; Orlowski R; Sachdev P; Shumaker R; Casado Herraez A
    J Clin Oncol; 2020 Sep; 38(26):2981-2992. PubMed ID: 32167863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma.
    Grünwald V; Larkin J; Puente J; Bedke J; Porta C
    Clin Genitourin Cancer; 2024 Apr; 22(2):394-401. PubMed ID: 38218660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
    Albiges L; Gurney H; Atduev V; Suarez C; Climent MA; Pook D; Tomczak P; Barthelemy P; Lee JL; Stus V; Ferguson T; Wiechno P; Gokmen E; Lacombe L; Gedye C; Perini RF; Sharma M; Peng X; Lee CH
    Lancet Oncol; 2023 Aug; 24(8):881-891. PubMed ID: 37451291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
    Makker V; Colombo N; Casado Herráez A; Monk BJ; Mackay H; Santin AD; Miller DS; Moore RG; Baron-Hay S; Ray-Coquard I; Ushijima K; Yonemori K; Kim YM; Guerra Alia EM; Sanli UA; Bird S; Orlowski R; McKenzie J; Okpara C; Barresi G; Lorusso D
    J Clin Oncol; 2023 Jun; 41(16):2904-2910. PubMed ID: 37058687
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization and Management of Adverse Reactions in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib.
    Jones A; Degregorio P; Sung MW; Ramji Z; Ren M; Baron AD
    J Adv Pract Oncol; 2023 Nov; 14(7):598-607. PubMed ID: 38196672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
    Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
    N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma.
    Lorusso D; Danesi R; Locati LD; Masi G; De Giorgi U; Gadducci A; Pignata S; Sabbatini R; Savarese A; Valabrega G; Zamagni C; Colombo N
    Front Oncol; 2022; 12():979519. PubMed ID: 36212444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
    Zammarrelli WA; Ma W; Espino K; Gordhandas S; Yeoshoua E; Ehmann S; Zhou Q; Iasonos A; Abu-Rustum NR; Aghajanian C; Green AK; Rubinstein MM; Makker V
    Gynecol Oncol; 2023 Nov; 178():27-35. PubMed ID: 37748268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
    Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
    Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system.
    Chiba Y; Kagabu M; Osakabe M; Ito R; Sato S; Takatori E; Kaido Y; Nagasawa T; Shoji T; Yanagawa N; Baba T
    Jpn J Clin Oncol; 2024 Apr; 54(4):424-433. PubMed ID: 38251744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.